Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nihon Chouzai Co ( (JP:3341) ) has shared an update.
Nihon Chouzai Co., Ltd. announced an extraordinary loss of ¥2,267 million due to advisory fees related to a tender offer by AP86 Co., Ltd. Despite this, the company exceeded its earnings forecast for the first half of the fiscal year, driven by higher-than-expected prescription prices and effective cost control. The company has revised its full-year forecast due to its scheduled delisting in December 2025, following an extraordinary general meeting decision.
The most recent analyst rating on (JP:3341) stock is a Hold with a Yen3834.00 price target. To see the full list of analyst forecasts on Nihon Chouzai Co stock, see the JP:3341 Stock Forecast page.
More about Nihon Chouzai Co
Nihon Chouzai Co., Ltd. operates in the healthcare industry, focusing primarily on dispensing pharmacy services and specialty pharmaceuticals. The company is listed on the Tokyo Stock Exchange Prime Market and is a significant player in Japan’s pharmaceutical sector.
Average Trading Volume: 171,137
Technical Sentiment Signal: Buy
Current Market Cap: Yen113.2B
For an in-depth examination of 3341 stock, go to TipRanks’ Overview page.